Biolase Technology (BIOL) 2.28 $BIOL
Federico Pignatelli Withdraws His Name as a BIOLASE Director Nominee
GlobeNewswire - Wed Apr 22, 7:00AM CDT
Federico Pignatelli, former Chairman and Chief Executive Officer of BIOLASE, Inc. (Nasdaq:BIOL), announces the withdrawal of his name from nomination as a Director of BIOLASE, Inc. (Nasdaq:BIOL).
BIOL: 2.28 (-0.33)
Buy LED Medical Before Your Dentist Does
Dallas Salazar - at Seeking Alpha - Thu Mar 26, 9:16AM CDT
SIRO: 93.81 (+0.60), PCTY: 31.29 (+0.64), ADP: 85.31 (+0.21), BIOL: 2.28 (-0.33), TNET: 35.45 (-0.54), PAYC: 32.95 (-0.16)
BIOLASE reports grant of stock options to CFO David C. Dreyer under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Mar 13, 6:18AM CDT
Medical device company BIOLASE (NASDAQ:BIOL) said on Thursday that it has awarded options to purchase 871,710 shares of its common stock to its CFO David C. Dreyer at an exercise price of USD1.99 per share, the closing price per share on 9 March 2015.
BIOL: 2.28 (-0.33)
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Thu Mar 12, 4:10PM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that on March 9, 2015, David C. Dreyer, the Company's Chief Financial Officer, received options to purchase 871,710 shares of the Company's common stock with an exercise price of $1.99 per share, the closing price per share on March 9, 2015. Subject to Mr. Dreyer's continued employment, the stock options shall vest and be exercisable as follows: 130,757 of the option shares shall vest and be exercisable on the one-year anniversary of the Executive's first date of employment; 10,896 of the option shares shall vest and be exercisable on each one-month anniversary following the one-year anniversary for a period of 35 consecutive months; 10,909 of the option shares shall vest and be exercisable on the 36-month anniversary; and 348,684 option shares shall vest and be exercisable on March 9, 2025.
BIOL: 2.28 (-0.33)
BIOLASE's (BIOL) CEO Jeff Nugent on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 04, 8:33PM CST
BIOL: 2.28 (-0.33)
Biolase reports 4Q loss
Automated Insights - Wed Mar 04, 3:54PM CST
IRVINE, Calif. (AP) _ Biolase Inc. (BIOL) on Wednesday reported a loss of $4.1 million in its fourth quarter.
BIOL: 2.28 (-0.33)
Biolase misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 3:11PM CST
BIOL: 2.28 (-0.33)
Biolase reports after the close
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 12:26PM CST
BIOL: 2.28 (-0.33)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 4:35PM CST
ERJ: 30.68 (-0.38), JONE: 9.59 (+0.16), BREW: 13.67 (+0.08), GTY: 17.71 (+0.10), WTI: 6.27 (-0.06), VSLR: 14.33 (+0.36), RNDY: 5.48 (-0.15), GEF: 39.11 (+0.37), SMTC: 25.78 (+0.06), ALSK: 1.99 (+0.01), SQNM: 4.47 (+0.08), POWR: 12.89 (+0.26), CPE: 8.62 (+0.12), PQ: 2.54 (+0.02), PPO: 58.63 (+0.12), ALIM: 4.92 (-0.09), BIOL: 2.28 (-0.33), SPOK: 20.73 (+0.23), PEIX: 12.25 (-0.30), DAR: 13.90 (+0.10), HRB: 32.32 (+0.16)
New finance chief at Biolase
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 6:16AM CST
BIOL: 2.28 (-0.33)
BIOLASE Names David C. Dreyer Chief Financial Officer
Business Wire - Mon Mar 02, 5:00AM CST
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it has hired veteran financial executive David C. Dreyer as its Chief Financial Officer. He will report to BIOLASE President and CEO Jeffrey M. Nugent and join the Company, effective March 9. Mr. Dreyer replaces Frederick D. Furry, who resigned January 31 to pursue other opportunities.
DPLO: 34.52 (+0.26), BIOL: 2.28 (-0.33)
Biolase CFO bids adieu
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:14PM CST
BIOL: 2.28 (-0.33)
BIOLASE Announces Management Change
Business Wire - Fri Feb 06, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Frederick D. Furry has resigned as Chief Financial Officer, effective January 31, 2015 to pursue other opportunities.
BIOL: 2.28 (-0.33)
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 1:43PM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.28 (-0.33)
Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 10:48AM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.28 (-0.33)
Medical Laser Systems - 2014 Global Strategic Business Report
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/q7pvtt/medical_laser) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services The report profiles 119 companies including many key and niche players such as: - AngioDynamics, Inc. - Bausch & Lomb Incorporated - BIOLASE, Inc. - Biolitec AG - Cardiogenesis Corporation Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 119 (including Divisions/Subsidiaries 145) - The United States (70) - Canada (3) - Japan (6) - Europe (53) - France (4) - Germany (22) - The United Kingdom (4) - Italy (7) - Spain (1) - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (10) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/q7...ical_laser
BIOL: 2.28 (-0.33)
Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020
M2 - Tue Dec 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcpwzv/global_dental) has announced the addition of the "Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020" report to their offering. The global dental market comprises dental implants, dental prosthesis, dental biomaterials, dental crowns and bridges, dental imaging, dental units and equipment. In the past decade, the market has experienced a swelling expansion due to a surge in the uptake of implants, crowns and cosmetic dentistry. The key factors igniting the market growth include poor oral hygiene, a rise in incidences of oral diseases on the back of a growing elderly population, an improvement in oral care needs of individuals and an increasing disposable income in developing economies. The acceptance and proliferation of technology in terms of dental imaging (3D imaging), design and manufacturing (CAD/CAM) has resulted in better diagnosis, dental designs, patient compliance and a decrease in chair time. Globally, the US is the leading market for dental care devices with its Centers for Medicare and Medicaid Services (CMS) having estimated the demand for dental services in the country to approach $167 billion by 2015. As per The Association of Dental Dealers of Europe (ADEE), in 2011, the European dental market increased by 1.2% in terms of the total turnover for all countries with the number of active dentists increasing slightly by 0.8%. Another key market is the Asia-Pacific region. Japan is a relatively mature market in the APAC region, whereas in developing countries like India and China, rising disposable income of the middle class as well as growing dental-care awareness and consumer acceptance are contributing to market growth. Companies Mentioned - A-Dec Inc. - Biolase Inc. - Danaher Corporation - GC CORPORATION - Henry Schein Inc. - Midmark Corporation - NAKANISHI INC. - Nobel Biocare - Patterson Dental Supply Inc. - Planmeca Oy - Sirona Dental Systems Inc. - Straumann (SIX) - Sybron Dental Specialties Inc. - Young Innovations Inc. For more information visit http://www.researchandmarkets.com/research/tc...bal_dental
SIRO: 93.81 (+0.60), BIOL: 2.28 (-0.33), DHR: 85.25 (+0.05), HSIC: 141.11 (+1.14)
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases and Poor Oral Hygiene: ABMRG
PR Newswire Europe - Tue Dec 09, 7:00AM CST
LONDON and NEW YORK, December 9, 2014 /PRNewswire/ --
SIRO: 93.81 (+0.60), BIOL: 2.28 (-0.33), PDCO: 47.34 (+0.13), SIX: 49.97 (+1.37), DHR: 85.25 (+0.05), HSIC: 141.11 (+1.14)
BIOLASE Launches New EPIC(TM) X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster
PR Newswire - Mon Dec 01, 3:37PM CST
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in lasers, today introduced the EPIC(TM) X diode laser, the company's premier and most complete diode laser for the whole dental team.
BIOL: 2.28 (-0.33)
Federico Pignatelli Withdraws His Name as a BIOLASE Director Nominee
GlobeNewswire - Wed Apr 22, 7:00AM CDT
Federico Pignatelli, former Chairman and Chief Executive Officer of BIOLASE, Inc. (Nasdaq:BIOL), announces the withdrawal of his name from nomination as a Director of BIOLASE, Inc. (Nasdaq:BIOL).
BIOL: 2.28 (-0.33)
Buy LED Medical Before Your Dentist Does
Dallas Salazar - at Seeking Alpha - Thu Mar 26, 9:16AM CDT
SIRO: 93.81 (+0.60), PCTY: 31.29 (+0.64), ADP: 85.31 (+0.21), BIOL: 2.28 (-0.33), TNET: 35.45 (-0.54), PAYC: 32.95 (-0.16)
BIOLASE reports grant of stock options to CFO David C. Dreyer under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Mar 13, 6:18AM CDT
Medical device company BIOLASE (NASDAQ:BIOL) said on Thursday that it has awarded options to purchase 871,710 shares of its common stock to its CFO David C. Dreyer at an exercise price of USD1.99 per share, the closing price per share on 9 March 2015.
BIOL: 2.28 (-0.33)
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Thu Mar 12, 4:10PM CDT
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that on March 9, 2015, David C. Dreyer, the Company's Chief Financial Officer, received options to purchase 871,710 shares of the Company's common stock with an exercise price of $1.99 per share, the closing price per share on March 9, 2015. Subject to Mr. Dreyer's continued employment, the stock options shall vest and be exercisable as follows: 130,757 of the option shares shall vest and be exercisable on the one-year anniversary of the Executive's first date of employment; 10,896 of the option shares shall vest and be exercisable on each one-month anniversary following the one-year anniversary for a period of 35 consecutive months; 10,909 of the option shares shall vest and be exercisable on the 36-month anniversary; and 348,684 option shares shall vest and be exercisable on March 9, 2025.
BIOL: 2.28 (-0.33)
BIOLASE's (BIOL) CEO Jeff Nugent on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 04, 8:33PM CST
BIOL: 2.28 (-0.33)
Biolase reports 4Q loss
Automated Insights - Wed Mar 04, 3:54PM CST
IRVINE, Calif. (AP) _ Biolase Inc. (BIOL) on Wednesday reported a loss of $4.1 million in its fourth quarter.
BIOL: 2.28 (-0.33)
Biolase misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 3:11PM CST
BIOL: 2.28 (-0.33)
Biolase reports after the close
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 12:26PM CST
BIOL: 2.28 (-0.33)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 4:35PM CST
ERJ: 30.68 (-0.38), JONE: 9.59 (+0.16), BREW: 13.67 (+0.08), GTY: 17.71 (+0.10), WTI: 6.27 (-0.06), VSLR: 14.33 (+0.36), RNDY: 5.48 (-0.15), GEF: 39.11 (+0.37), SMTC: 25.78 (+0.06), ALSK: 1.99 (+0.01), SQNM: 4.47 (+0.08), POWR: 12.89 (+0.26), CPE: 8.62 (+0.12), PQ: 2.54 (+0.02), PPO: 58.63 (+0.12), ALIM: 4.92 (-0.09), BIOL: 2.28 (-0.33), SPOK: 20.73 (+0.23), PEIX: 12.25 (-0.30), DAR: 13.90 (+0.10), HRB: 32.32 (+0.16)
New finance chief at Biolase
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 6:16AM CST
BIOL: 2.28 (-0.33)
BIOLASE Names David C. Dreyer Chief Financial Officer
Business Wire - Mon Mar 02, 5:00AM CST
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it has hired veteran financial executive David C. Dreyer as its Chief Financial Officer. He will report to BIOLASE President and CEO Jeffrey M. Nugent and join the Company, effective March 9. Mr. Dreyer replaces Frederick D. Furry, who resigned January 31 to pursue other opportunities.
DPLO: 34.52 (+0.26), BIOL: 2.28 (-0.33)
Biolase CFO bids adieu
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:14PM CST
BIOL: 2.28 (-0.33)
BIOLASE Announces Management Change
Business Wire - Fri Feb 06, 3:05PM CST
BIOLASE, Inc. (NASDAQ:BIOL), the world's leading manufacturer and distributor of dental lasers, today reported that Frederick D. Furry has resigned as Chief Financial Officer, effective January 31, 2015 to pursue other opportunities.
BIOL: 2.28 (-0.33)
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 1:43PM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.28 (-0.33)
Viral Cross-Contamination Risks at the Dentist Office
Marketwired - Wed Jan 14, 10:48AM CST
Capital Market Relations, a capital markets advisory firm dedicated to helping organizations advance new standards, has announced a new report is available on capitalmarketreport.com. Capital Market Luminary Chris Rosgen was recently interviewed on Clear Channel's - iHeart Business Talk Radio's with Michael Yorba on The Traders Network. The focus of both the Capital Market Report and radio interviews discussed identifying new standards of care in laser medicine and how most US patients are unaware of the risks at the dentist office including the fact that 15% of "sterilized" burs and up to 76% of "sterilized" endodontic files used in root canals may carry life-threatening pathogenic micro-organisms. Source: Biolase http://www.biolase.com/Pages/Cross-Contamination.aspx
BIOL: 2.28 (-0.33)
Medical Laser Systems - 2014 Global Strategic Business Report
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/q7pvtt/medical_laser) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services The report profiles 119 companies including many key and niche players such as: - AngioDynamics, Inc. - Bausch & Lomb Incorporated - BIOLASE, Inc. - Biolitec AG - Cardiogenesis Corporation Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 119 (including Divisions/Subsidiaries 145) - The United States (70) - Canada (3) - Japan (6) - Europe (53) - France (4) - Germany (22) - The United Kingdom (4) - Italy (7) - Spain (1) - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (10) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/q7...ical_laser
BIOL: 2.28 (-0.33)
Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020
M2 - Tue Dec 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/tcpwzv/global_dental) has announced the addition of the "Global Dental Devices, Dental Implants And Dental Diagnostic Devices Market Through 2020" report to their offering. The global dental market comprises dental implants, dental prosthesis, dental biomaterials, dental crowns and bridges, dental imaging, dental units and equipment. In the past decade, the market has experienced a swelling expansion due to a surge in the uptake of implants, crowns and cosmetic dentistry. The key factors igniting the market growth include poor oral hygiene, a rise in incidences of oral diseases on the back of a growing elderly population, an improvement in oral care needs of individuals and an increasing disposable income in developing economies. The acceptance and proliferation of technology in terms of dental imaging (3D imaging), design and manufacturing (CAD/CAM) has resulted in better diagnosis, dental designs, patient compliance and a decrease in chair time. Globally, the US is the leading market for dental care devices with its Centers for Medicare and Medicaid Services (CMS) having estimated the demand for dental services in the country to approach $167 billion by 2015. As per The Association of Dental Dealers of Europe (ADEE), in 2011, the European dental market increased by 1.2% in terms of the total turnover for all countries with the number of active dentists increasing slightly by 0.8%. Another key market is the Asia-Pacific region. Japan is a relatively mature market in the APAC region, whereas in developing countries like India and China, rising disposable income of the middle class as well as growing dental-care awareness and consumer acceptance are contributing to market growth. Companies Mentioned - A-Dec Inc. - Biolase Inc. - Danaher Corporation - GC CORPORATION - Henry Schein Inc. - Midmark Corporation - NAKANISHI INC. - Nobel Biocare - Patterson Dental Supply Inc. - Planmeca Oy - Sirona Dental Systems Inc. - Straumann (SIX) - Sybron Dental Specialties Inc. - Young Innovations Inc. For more information visit http://www.researchandmarkets.com/research/tc...bal_dental
SIRO: 93.81 (+0.60), BIOL: 2.28 (-0.33), DHR: 85.25 (+0.05), HSIC: 141.11 (+1.14)
The Global Dental Device Market to hit $12.7 Billion by 2020 Propelled by a Surge in Oral Diseases and Poor Oral Hygiene: ABMRG
PR Newswire Europe - Tue Dec 09, 7:00AM CST
LONDON and NEW YORK, December 9, 2014 /PRNewswire/ --
SIRO: 93.81 (+0.60), BIOL: 2.28 (-0.33), PDCO: 47.34 (+0.13), SIX: 49.97 (+1.37), DHR: 85.25 (+0.05), HSIC: 141.11 (+1.14)
BIOLASE Launches New EPIC(TM) X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster
PR Newswire - Mon Dec 01, 3:37PM CST
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in lasers, today introduced the EPIC(TM) X diode laser, the company's premier and most complete diode laser for the whole dental team.
BIOL: 2.28 (-0.33)
